, Tracking Stock Market Picks
Enter Symbol:
Corcept Therapeutics Incorporated (CORT) [hlAlert]

down 15.77 %

Corcept Therapeutics Incorporated (CORT) rated Underperform by BofA/Merrill

Posted on: Friday,  Jul 13, 2012  8:25 AM ET by BofA/Merrill

BofA/Merrill rated Underperform Corcept Therapeutics Incorporated (NASDAQ: CORT) on 07/13/2012, when the stock price was $4.27. Since
then, Corcept Therapeutics Incorporated has gained 18.74% as of 01/15/2016's recent price of $5.07.
If you would have followed this BofA/Merrill's recommendation on CORT, you would have lost 15.77% of your investment in 1281 days.

Corcept Therapeutics Incorporated (Corcept) is a pharmaceutical company engaged in the development of drugs for the treatment of severe psychiatric and metabolic diseases. The Company focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Corcept's principal product candidate, CORLUX, modulates the effect of cortisol by selectively blocking the binding of cortisol to one of its two known receptors, the GR-II receptor, also known as the Type II or GR receptor.

Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/13/2012 8:25 AM Sell
as of 12/31/2012
1 Week up  5.92 %
1 Month up  0.69 %
3 Months up  48.74 %
1 YTD up  66.51 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy